Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Curis Inc (NQ: CRIS )

11.50 USD -0.33 (-2.79%)
Official Closing Price Updated: 7:54 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Curis Inc

< Previous 1 2 3 Next >
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2021, the independent... 
From PR Newswire
Curis to Present at 20th Annual Needham Virtual Healthcare Conference
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive... 
From PR Newswire
Curis Reports Fourth Quarter and Year-End 2020 Financial Results
- Significantly expanded IRAK4 inhibitor CA-4948 development to include Phase 1 CA-4948 monotherapy study in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), Phase 1 CA-4948/ibrutinib... 
From PR Newswire
Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that an abstract for CA-4948, a small molecule... 
From PR Newswire
Curis to Release Fourth Quarter 2020 Financial Results and Hold Conference Call on March 16, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter... 
From PR Newswire
Curis to Present at H.C. Wainwright & Co. Global Life Sciences Conference
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive... 
From PR Newswire
Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive... 
From PR Newswire
Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies
- Amends existing protocol of ongoing Phase 1 study in R/R NHL - 
From PR Newswire
Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes
- Phase 2 study sponsored by investigators at Universität Leipzig in Germany - 
From PR Newswire
Thinking about buying stock in GameStop, AMC Entertainment, Novavax, Riot Blockchain, or Curis?
InvestorsObserver issues critical PriceWatch Alerts for GME, AMC, NVAX, RIOT, and CRIS. 
From PR Newswire
Curis to Present at B. Riley Securities Virtual Oncology Investor Conference
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive... 
From PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 4, 2021, the independent... 
From PR Newswire
Curis to Present at H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive... 
From PR Newswire
CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors
From GlobeNewswire News Releases
Small Cap Momentum Stories to Watch (NASDAQ: BLNK) (OTC US: MMEDF) (OTC US: CLKA) (NASDAQ: CRIS)
Tags Small Business Environment Shareholders
From OTC
SAB Biotherapeutics Announces New Appointments to its Board of Directors
SAB Biotherapeutics Announces New Appointments to its Board of Directors 
From Business Wire News Releases
Curis Announces Closing of Public Offering of Common Stock with $169.6 Million in Gross Proceeds, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the closing of its underwritten public offering of... 
From PR Newswire
Curis Announces Pricing of Public Offering of Common Stock
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the pricing of an underwritten public offering of... 
From PR Newswire
Thinking about buying stock in Rocket Pharmaceuticals, Sorrento Therapeutics, Intec Pharma, Cinedigm Corp, or Curis Inc?
InvestorsObserver issues critical PriceWatch Alerts for RCKT, SRNE, NTEC, CIDM, and CRIS. 
From PR Newswire
Curis Announces Proposed Public Offering of Common Stock
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced its intention to offer and sell shares of its... 
From PR Newswire
Thinking about buying stock in Curis, Blink Charging, BioCryst Pharmaceuticals, Electrameccanica Vehicles, or Uranium Energy?
InvestorsObserver issues critical PriceWatch Alerts for CRIS, BLNK, BCRX, SOLO, and UEC. 
From PR Newswire
Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Reduction of marrow blasts observed in all evaluable patients - 
From PR Newswire
Curis Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's Lymph
- Tumor reductions observed in 6 of 7 patients treated at 300 mg BID following median 4 prior lines of therapy - 
From PR Newswire
Curis to Host Virtual Event to Discuss CA-4948 Clinical Data
- KOL Event featuring Dr. Amit Verma scheduled for Tuesday, December 8 at 8:00 a.m. ET - 
From PR Newswire
Curis Reports Third Quarter 2020 Financial Results
- Clinical data in CA-4948 NHL and AML/MDS trials to be presented in oral presentation and poster sessions at ASH - 
From PR Newswire
Curis Announces Collaboration with the National Cancer Institute for the Development of IRAK4 Inhibitor, CA-4948, as an Anti-Cancer Agent
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into a Cooperative Research... 
From PR Newswire
Curis Announces Three Abstracts for CA-4948 Accepted for Presentation at the 62nd American Society of Hematology Annual Meeting and Exposition
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that three abstracts for CA-4948, a small molecule... 
From PR Newswire
Curis to Present at H.C. Wainwright & Co. 6th Annual Israel Conference
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive... 
From PR Newswire
Curis to Release Third Quarter 2020 Financial Results and Hold Conference Call on November 10, 2020
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter... 
From PR Newswire
Curis Highlights Publication in ACS Medicinal Chemistry Letters Showcasing Targeted Potency and Ideal Pharmacologic Properties of CA-4948 for Treatment of Hematologic Malignancies
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today highlighted a paper published online in ACS Medicinal... 
From PR Newswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.